DWP 708
Alternative Names: DWP-708Latest Information Update: 26 Dec 2022
At a glance
- Originator Daewoong Pharmaceutical
- Class Anti-inflammatories; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acneiform eruptions
Most Recent Events
- 26 Dec 2022 DWP 708 is still in phase-II trials for Acneiform eruptions in South Korea (NCT05378360)
- 02 May 2022 Daewoong Pharmaceutical initiates enrolment in a phase-II clinical trials in Acneiform eruptions in South Korea (Topical, Cream) (NCT05378360)
- 23 Oct 2020 Phase-II clinical trials in Acneiform eruptions in South Korea (Topical) (Daewoong Pharmaceutical pipeline, October 2020)